Francis Barany

Francis Barany is a Professor of Microbiology and Immunology at Weill Cornell Medical College (WCMC), Cornell University. His research focuses on molecular diagnostics, cancer genetics, and epigenetic mechanisms, with a particular emphasis on developing innovative diagnostic assays and targeted therapies. He leads the Francis Barany Lab, which explores areas such as proteolysis-targeting chimeras (PROTACs), epigenetic biomarkers, and next-generation sequencing technologies.

Dr. Barany holds a Ph.D. from The Rockefeller University (1981) and a B.A. from the University of Illinois (1976). His work integrates molecular biology, biochemistry, and clinical oncology to address challenges in cancer detection, drug resistance, and personalized medicine. Key research interests include:

• Development of multiplex PCR-based diagnostic platforms for cancer and infectious diseases
• Epigenetic regulation of tumor progression and immune infiltration
• Targeted protein degradation using self-assembling drug molecules
• Molecular profiling of colorectal, prostate, and breast cancers

Recent publications highlight advancements in PROTAC technologies, liquid biopsy approaches for cancer detection, and epigenetic biomarker discovery. Dr. Barany has secured grant funding from organizations like Oxford Nanopore Technologies and Acuamark Diagnostics, supporting projects on next-generation sequencing and diagnostic assay development. He holds proprietary interests in companies like Acuamark and Chiara Biosciences, reflecting his translational research impact.

In addition to academic contributions, he serves as an advisor and consultant to pharmaceutical and biotech entities, fostering industry-academia collaboration. His lab collaborates with researchers across disciplines to advance biomedical innovation and precision medicine strategies.